PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2019 January; 10(1): e0002. ISSN: 2076-9172Published online 2019 January 28. doi: 10.5041/RMMJ.10339.

Table 5.

Pathological Parameters in Both Groups.

Parameter	Neoadjuvant Chemotherapy (NACT; n=22)	Neoadjuvant Chemoradiotherapy (NACRT; n=33)	P value
R0 resection	19 (86%)	29 (88%)	1

R1 resection	3 (14%)	4 (12%)	1

Tumor regression grading (TRG) score			0.019
Complete (0)	3	15
Moderate (1)	1	5
Minimal (2)	8	9
Poor (3)	10	4

TRG 0	3 (14%)	15 (45.5%)	0.019
TRG 1/2/3	19 (86%)	18 (54.5%)

LVI	10 (45%)	5 (15%)	0.0284

PNI	4 (18%)	6 (18%)	1

Down-staging effect on primary tumor			0.019
pT0	3 (13.6%)	15 (45%)
pT1/2/3/4	19 (86.4%)	18 (55%)

Down-staging effect on nodes			0.5533
pN0	15 (68%)	25 (76%)
pN1/2/3	7 (32%)	8 (24%)

Pathological complete response	3 (13.6%)	13 (39.4%)	0.0675

Median tumor size (cm)	2.5	0.2	0.0005

No. of lymph nodes resected			0.1872
Median	13	11
Range	8–32	2–26

No. of positive lymph nodes			0.5485
Mean	1.72	0.72
Range	0–11	0–6

LVI, lymphovascular invasion; PNI, perineural invasion; R0 resection, microscopically margin-negative resection; R1 resection, removal of all macroscopic disease, but microscopic margins are positive for tumor.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2019 January; 10(1): e0002. ISSN: 2076-9172

Published online 2019 January 28. doi: 10.5041/RMMJ.10339